EVLO - Evelo Biosciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.3400
+0.1000 (+2.36%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close4.2400
Open4.2900
Bid4.1200 x 1400
Ask4.5900 x 1000
Day's Range4.2900 - 4.3600
52 Week Range3.5800 - 10.4400
Volume22,270
Avg. Volume61,327
Market Cap139.252M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • GlobeNewswire

    Evelo Provides Update on Recent Positive EDP1815 Regulatory Interactions on Phase 2 Trial Design Resulting in Shorter Development Timeline to Registration

    Evelo Biosciences, Inc. (EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today provided an update on recent positive regulatory interactions on the EDP1815 Phase 2 trial design, resulting in a reduction in the overall development plan timeline to registration. In 2019, we reported positive clinical data with EDP1815 in individuals with psoriasis, which was the first clinical evidence of the promise that Sintax holds as a new drug target.

  • Flagship Unveils Newest Pioneering Platform: Ring Therapeutics
    PR Newswire

    Flagship Unveils Newest Pioneering Platform: Ring Therapeutics

    Flagship Pioneering, a unique life sciences innovation enterprise, today announced the launch of Ring Therapeutics, an early-stage biotechnology company developing first-in-class gene therapies using a new viral vector platform based on its groundbreaking work on the human commensal virome. Ring's technology promises to address many of the limitations of current DNA and gene therapies, such as limited access to diverse tissues, inability to redose, risk of genomic integration, and poor tolerability. Ring's founding and continued development are resourced by an initial capital commitment of $50 million from Flagship Pioneering.

  • GlobeNewswire

    Evelo Biosciences Appoints Juan Andres to Board of Directors

    Evelo Biosciences, Inc. (EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced the appointment of biopharmaceutical industry veteran Juan Andres to its Board of Directors. “We are pleased to welcome Juan to our Board during an important time in Evelo’s growth,” said David Epstein, Chairman of the Evelo Board of Directors.

  • GlobeNewswire

    Evelo Biosciences to Present at the Stifel 2019 Healthcare Conference

    Evelo Biosciences, Inc. (EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that management will present a corporate overview at the Stifel 2019 Healthcare Conference on Wednesday, November 20th at 2:25pm EST. A live audio webcast of the presentation will be available on the Investors section of the Evelo website at http://ir.evelobio.com/news-events. Evelo Biosciences, Inc. is a clinical stage biotechnology company developing oral biologics that act on cells in the small intestine with systemic therapeutic effects.

  • GlobeNewswire

    Evelo Biosciences to Present Preclinical Data from its EDP1503 Oncology Program at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting

    CAMBRIDGE, Mass., Nov. 08, 2019 -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting.

  • GlobeNewswire

    Evelo Biosciences Reports Further Positive EDP1815 Interim Clinical Data in Patients with Psoriasis at High Dose in Phase 1b Trial

    Evelo Biosciences (EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced positive interim clinical data in an ongoing Phase 1b trial in individuals with mild to moderate psoriasis treated with a high dose of EDP1815, its clinical candidate for the treatment of a range of inflammatory diseases. Eighteen individuals with mild to moderate psoriasis were randomized 2:1 to receive a daily oral administration of 2.76g (5x or high dose) of EDP1815 or placebo for 28 days.

  • GlobeNewswire

    Evelo Biosciences Announces Further Positive Interim Phase 1b Clinical Data in Psoriasis and Reports Third Quarter 2019 Financial Results

    --EDP1815 was Well Tolerated with No Overall Difference Reported from Placebo----Reduction in Mean Lesion Severity Score (LSS) at 28 Days Consistent between High and Low Dose.

  • GlobeNewswire

    Evelo Biosciences to Host Quarterly Corporate Update Conference Call on Tuesday, November 5th 

    Evelo Biosciences (EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that it will host a conference call and live webcast at 8:30 A.M. ET on Tuesday, November 5, 2019 to report its third quarter financial results and discuss recent business updates. A live webcast of the event will also be available under “News and Events” in the Investors section of Evelo's website at http://ir.evelobio.com. The archived webcast will be available on Evelo's website approximately two hours after the completion of the event and will be available for 30 days following the call.

  • GlobeNewswire

    Evelo Biosciences to Present at the 2019 Cantor Global Healthcare Conference

    CAMBRIDGE, Mass,, Sept. 26, 2019 -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing orally delivered, systemically acting biologics,.

  • GlobeNewswire

    Evelo Biosciences to Host Key Opinion Leader Symposium on Unmet Need in Mild to Moderate Psoriasis and Potential for EDP1815

    Evelo Biosciences, Inc. (EVLO), a clinical stage biotechnology company developing orally delivered, systemically acting biologics, today announced that it will host a key opinion leader symposium on the unmet need in mild to moderate psoriasis and the potential for EDP1815 as a new therapeutic option for patients. As part of the event, Mark G. Lebwohl, M.D., Waldman Professor and Chairman of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai, will present an overview of the current treatment landscape and burden of disease in mild to moderate psoriasis. Additionally, Evelo management will review the recently announced positive interim clinical data from its ongoing Phase 1b clinical trial evaluating EDP1815 in mild to moderate psoriasis, and discuss its planned path forward in psoriasis and broader significance to the Company’s platform.

  • GlobeNewswire

    Evelo Biosciences Announces the Appointment of David Epstein as Chairman of its Board of Directors

    Evelo Biosciences, Inc. (EVLO), a clinical stage biotechnology company developing orally delivered, systemically acting biologics, announced today that David Epstein has been appointed chairman of its Board of Directors. Mr. Epstein has been a director of Evelo since March 2017. Noubar Afeyan, Ph.D., a co-founder of Evelo and chief executive officer of Flagship Pioneering, is stepping down after serving as chairman of the Board since Evelo’s founding in 2014.

  • GlobeNewswire

    Evelo Biosciences to Present at the Morgan Stanley 17th Annual Global Healthcare Conference

    Evelo Biosciences, Inc. (EVLO), a biotechnology company developing oral biologics that act on cells in the small intestine with systemic therapeutic effects, today announced that management will participate in a fireside chat at the Morgan Stanley 17th Annual Global Healthcare Conference on Tuesday, September 10th at 10:35 am ET. A live audio webcast of the fireside chat will be available on the Investors section of the Evelo website at http://ir.evelobio.com/news-events. Evelo Biosciences, Inc. is a clinical stage biotechnology company developing oral biologics that act on cells in the small intestine with systemic therapeutic effects.

  • GlobeNewswire

    Evelo Biosciences Reports Positive EDP1815 Interim Clinical Data in Psoriasis Patients at Low Dose in Ongoing Phase 1b Trial

    Evelo Biosciences, Inc. (EVLO), a biotechnology company developing oral biologics that act on cells in the small intestine with systemic therapeutic effects, today announced positive interim clinical data from the first cohort of patients with mild to moderate psoriasis from its ongoing Phase 1b trial of EDP1815, its clinical candidate for the treatment of inflammatory diseases. 12 patients with mild to moderate psoriasis were randomized 2:1 to receive daily, oral administration of 550mg (1x dose) of EDP1815, or placebo, for 28 days. Secondary and exploratory endpoints included lesion severity score (LSS), a measure of clinical activity, cellular histological biomarkers and blood immune cell biomarkers taken from biopsies and blood samples, respectively, at the start and end of the 28-day dosing period.

  • GlobeNewswire

    Evelo Biosciences Announces Positive Interim Phase 1b Clinical Data and Provides Second Quarter 2019 Financial Results

    -EDP1815 and EDP1066 were Well Tolerated with No Overall Difference Reported from Placebo--Clinical Response Observed Consistent with Reductions in Cellular Histological and.

  • GlobeNewswire

    Evelo Biosciences to Host Quarterly Corporate Update Conference Call on Tuesday, August 6th

    Evelo Biosciences, Inc. (EVLO) (“Evelo”), a biotechnology company developing oral biologics that act on cells in the small intestine with systemic therapeutic effects, today announced that it will host a conference call and live webcast at 8:30 A.M. ET on Tuesday, August 6, 2019 to report its second quarter financial results and discuss recent business updates. A live webcast of the event will also be available under “News and Events” in the Investors section of Evelo's website at http://ir.evelobio.com. The archived webcast will be available on Evelo's website approximately two hours after the completion of the event and will be available for 30 days following the call.

  • GlobeNewswire

    Evelo Biosciences Secures $45 Million Debt Financing from K2 HealthVentures

    Evelo Biosciences, Inc. (EVLO), a biotechnology company developing oral biologics that act on cells in the small intestine with systemic therapeutic effects, today announced that it has entered into a loan and security agreement for up to $45 million with K2 HealthVentures (K2HV), a healthcare investment firm. “We are pleased to announce this agreement, which increases our financial flexibility as we advance our clinical portfolio of oral biologics in inflammation and oncology,” said Jonathan Poole, chief financial officer of Evelo.

  • GlobeNewswire

    Kaleido Biosciences Announces Appointment of Theo Melas-Kyriazi to its Board of Directors

    Kaleido Biosciences, Inc. (KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health, today announced that Theo Melas-Kyriazi, Executive Partner at Flagship Pioneering, has been appointed to its Board of Directors. In addition, the Company announced that Noubar Afeyan, Ph.D., co-founder of Kaleido and CEO of Flagship Pioneering, is stepping down after serving as a Board member since Kaleido’s founding within Flagship Labs in 2015.

  • GlobeNewswire

    Evelo Biosciences to Present at Upcoming Investor Conferences in June

    CAMBRIDGE, Mass., May 30, 2019 -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a clinical stage biotechnology company developing oral biologics that act on cells in the.

  • GlobeNewswire

    Evelo Biosciences to Present at 2019 RBC Capital Markets Global Healthcare Conference

    Evelo Biosciences, Inc. (EVLO) (“Evelo”), a clinical stage biotechnology company developing oral biologics that act on cells in the small intestine with striking therapeutic effects throughout the body, today announced that management will present a corporate overview at the 2019 RBC Capital Markets Global Healthcare Conference on Wednesday, May 22nd at 8:30am ET. A live audio webcast of the presentation will be available on the Investors section of the Evelo website at http://ir.evelobio.com/news-events. Evelo Biosciences, Inc. is a clinical stage biotechnology company developing oral biologics that act on cells in the small intestine with striking therapeutic effects throughout the body.

  • GlobeNewswire

    Evelo Biosciences Reports First Quarter 2019 Financial Results and Recent Business Highlights

    -- Novel Formulation of Monoclonal Microbials Discovered, Preclinical Potency Increased by up to 30-Fold:Plan to Introduce New Formulation into Ongoing Clinical Trials in Second.

  • GlobeNewswire

    Evelo Biosciences to Host Quarterly Corporate Update Conference Call on Thursday, May 2, 2019

    Evelo Biosciences, Inc. (EVLO) (“Evelo”), a clinical stage biotechnology company developing monoclonal microbials, a potential new modality of oral biologic medicines, today announced that it will host a conference call and live webcast at 8:30 A.M. ET on Thursday, May 2, 2019 to report its first quarter financial results and discuss recent business updates. A live webcast of the event will also be available under “News and Events” in the Investors section of Evelo's website at http://ir.evelobio.com. The archived webcast will be available on Evelo's website approximately two hours after the completion of the event and will be available for 30 days following the call.

  • GlobeNewswire

    Evelo Biosciences to Present at 18th Annual Needham Healthcare Conference

    Evelo Biosciences, Inc. (EVLO) (“Evelo”),  a clinical stage biotechnology company developing monoclonal microbials, a potential new modality of oral biologic medicines, today announced that management will present a corporate overview at the 18th Annual Needham Healthcare Conference on Wednesday, April 10th at 2:10pm ET. Evelo Biosciences, Inc. is a clinical-stage biotechnology company developing monoclonal microbials, a potential new modality of oral biologic medicines. Evelo’s product candidates are single strains of microbes, selected for defined pharmacological properties.

  • GlobeNewswire

    Evelo Biosciences to Present at 39th Annual Cowen & Co. Health Care Conference

    CAMBRIDGE, Mass., March 04, 2019 -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a clinical stage biotechnology company developing monoclonal microbials, a potential new.

  • GlobeNewswire

    Evelo Biosciences Reports Fourth Quarter and Full Year 2018 Financial Results and Business Highlights

    -- First Patient Dosed in University of Chicago Phase 2a Trial of EDP1503 in Metastatic Melanoma ---- Preclinical Studies Have Shown Non-replicating Monoclonal Microbials.

  • GlobeNewswire

    Evelo Biosciences to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, February 14, 2019

    Evelo Biosciences, Inc. (EVLO) (“Evelo”), a clinical stage biotechnology company developing monoclonal microbials, a potential new modality of oral biologic medicines, today announced that it will host a conference call and live webcast at 8:30 A.M. ET on Thursday, February 14, 2019 to report its fourth quarter and full year 2018 financial results and discuss recent business updates. A live webcast of the event will also be available under “News and Events” in the Investors section of Evelo's website at http://ir.evelobio.com. The archived webcast will be available on Evelo's website approximately two hours after the completion of the event and will be available for 30 days following the call.